The MHRA has launched a consultation on whether the painkiller Nuromol should be available to patients without having to visit a pharmacy. 

The product contains paracetamol and ibuprofen and is indicated for mild to moderate pain when either paracetamol or ibuprofen alone have not relieved a patient’s pain adequately.  If reclassified from P medicine to GSL status, it will be sold in packs of six.

The MHRA said it was “committed to making medicines easier to access where it is safe to do so,” and wanted to hear from those who may be affected by the proposed reclassification.

The consultation is open until June 3.

MHRA risk management director Dr Sarah branch said: “Every response received will help us gain a better picture of whether people think Nuromol can be made available safely without the need to visit a pharmacy.

“We want to hear from as many people as possible, and therefore we urge people to respond to our consultation and let us know their views.”